Shin Nippon Biomedical Laboratories President Hirama Hideyuki (平間英之), the first president from outside the founding family, has outlined a policy of deepening the company’s existing businesses and expanding overseas as it seeks to become a global company.
Shin Nippon Biomedical Laboratories’ new president, Hirama Hideyuki (平間英之), took office this June. Born in Chiba, he graduated from the University of Tokyo’s Faculty of Law, joined the company after working at a financial institution, and has been involved in launching its overseas operations. As the first president from outside the founding family, he leads an organization of approximately 1,500 employees.
Looking ahead, he identified deepening the company’s existing businesses and taking on new challenges, and outlined his aim of globalizing the company.
Shin Nippon Biomedical Laboratories is headquartered in Kagoshima City and was founded in 1957. It provides contract pharmaceutical development services and maintains the leading domestic market share in preclinical testing, with more than half of its customers overseas. Annual revenue is approximately ¥32.5 billion.
Drawing on his experience taking on challenges in the IT sector, Hirama Hideyuki (平間英之) emphasized the promotion of digitalization. He outlined a policy of exploring new approaches to drug discovery that make greater use of IT and AI, with growth driven by the two pillars of overseas expansion and digital innovation.
In terms of human resources, women account for 24% of managers, while parental leave uptake has reached 100% for both men and women. The company is leveraging its childcare support, which was the first in the prefecture to receive national certification at this level, and positioning the advancement of women as a pillar of its growth strategy.